Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.57 |
| ▸ | TK2 | O00142 | 4/20 | 0.53 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18852615 | 1.00 | PYGM (0.57) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15810677 | 1.00 | PYGM (0.57) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL16805348 | 1.00 | PYGM (0.57) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18740741 | 0.91 | TK2 (0.49) | PYGMTK2 | |
| SCHEMBL16807689 | 0.91 | PYGM (0.59) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL29188121 | 0.88 | PYGM (0.53) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18503568 | 0.88 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL40819 | 0.88 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18512919 | 0.88 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18512917 | 0.88 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118176209-A | Treatment involving non-immunogenic RNA and PD-1 axis binding antagonists for antigen vaccination | 生物技术公司 | 2024-06-11 | — | — | CN | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| EP-4306643-A2 | PLASMID CONTAINING A SEQUENCE ENCODING AN MRNA WITH A SEGMENTED POLY(A) TAIL | ethris GmbH (DE) | 2024-01-17 | — | — | EP | claimed |
| CN-117413065-A | Constructs, methods and uses for the preparation of circular RNAs | 上海环码生物医药有限公司 | 2024-01-16 | — | — | CN | claimed |
| EP-3656872-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | Novartis AG (CH) | 2020-05-27 | — | — | EP | claimed |
| EP-3387150-B1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2019-10-02 | — | — | EP | claimed |
| EP-3387150-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | Novartis AG (CH) | 2018-10-17 | — | — | EP | claimed |
| US-9719084-B2 | Co-transcriptional assembly of modified RNA nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-08-01 | — | — | US | claimed |
| WO-2017098468-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2017-06-15 | — | — | WO | claimed |
| US-20150203842-A1 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2015-07-23 | — | — | US | claimed |
| WO-2014039809-A2 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2014-03-13 | — | — | WO | claimed |
| EP-2578685-A2 | RNA containing modified nucleosides and methods of use thereof | The Trustees of The University of Pennsylvania (US) | 2013-04-10 | — | — | EP | claimed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| CN-120129702-A | RNA compositions targeting claudin-18.2 | 生物技术公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-120092014-A | RNA constructs and uses thereof | 生物技术欧洲股份公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-119968210-A | RNA for preventing or treating tuberculosis | 生物技术公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2007024708-A2 | RNA CONTAINING MODIFIED NUCLEOSIDES AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | disclosed |
| EP-1221615-A2 | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy | ORIDIGM CORPORATION (US) | 2002-07-10 | — | — | EP | disclosed |
| US-6020139-A | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy | ORIDIGM CORPORATION (US) | 2000-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | RBP4, RBP1, VDR | PYGM 598/4885TK2 3708/4885SLC28A1 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.